Citations

Mayo Clinic

Showing 10 of 108551 citations.

Refractory Hypoxemia and Use of Rescue Strategies. A U.S. National Survey of Adult Intensivists
Alhurani, Rabe E., Oeckler, Richard A. , Jenkins, Sarah M. , Pannu, Sonal , Pannu, Sonal R, Franco, Pablo Moreno , Gajic, Ognjen

Annals of the American Thoracic Society | April 29, 2016 | Volume: 13 | Issue: 7 | Pages: 1105-1114

10.1513/annalsats.201508-560oc | PMID 27128143 Get It

Abstract Rationale The management of severe and refractory hypoxemia in critically ill adult patients is practice based. Variability across individual practitioners and institutions is not well documented. Objectives To conduct a nationwide survey of critical care physicians in the United States regarding accepted definitions and management strategies for severe and refractory hypoxemia. Methods A web-based survey was distributed to a stratified random sample of adult intensivists listed in the American Medical Association Physician Masterfile. The survey was generated by using a mixed-methods approach. Measurements and Main Results: In the survey, 4,865 e-mails were sent and 791 (16.3%) were opened. Among those who opened the e-mail message, 50% (n = 396) responded, representing 8.1% of total surveys sent. Seventy-two percent stated that their institutions lacked a protocol for identification and management of severe or refractory hypoxemia in the setting of acute respiratory failure. While the majority of respondents used low-Vt ventilation (81%), high positive end-expiratory pressure (86%), recruitment maneuvers (89%), and either bolus or infusion neuromuscular blockade (94%), there was marked variability in the use of specific rescue strategies as tier 1 or 2 interventions: prone position (27.8% vs. 47.8%, respectively), extracorporeal membrane oxygenation (2.3% vs. 51.2%, respectively), airway pressure release ventilation (49% vs. 34.5%, respectively), inhaled vasodilators (30.1% vs. 40%, respectively), and high-frequency oscillatory ventilation (7.8% vs. 40%, respectively). The variability was partly explained by providers’ expertise with particular rescue strategies (77.7%), advance directives (70.1%), the training of allied health staff (62.3%), and institutional availability (53.8%). Conclusions U.S. adult critical care physicians predominantly employ lung-protective ventilation for severe hypoxemia. A wide variation in other rescue strategies is noted, which is partly explained by user expertise and availability. Less than 30% institutions have formal protocols for management of refractory hypoxemia.
Harnessing the Power of the Host: Improving Dendritic Cell Vaccines for Malignant Pleural Mesothelioma
Peikert, Tobias, Sterman, Daniel H.

American Journal of Respiratory and Critical Care Medicine | April 29, 2016 | Volume: 193 | Issue: 9 | Pages: 943-945

10.1164/rccm.201512-2444ed | PMID 27128703 Get It

Antibody-Targeted Chemotherapy for the Treatment of Melanoma
Nevala, Wendy K. , Buhrow, Sarah A. , Knauer, Daniel J., Atanasova, Elena, Reid, Joel M. , Atanasova, Elena A, Markovic, Svetomir N.

Cancer Research | April 29, 2016 | Volume: 76 | Issue: 13 | Pages: 3954-3964

10.1158/0008-5472.can-15-3131 | PMID 27197186 Get It

Abstract Antibody-directed chemotherapy (ADC) offers an advantage over conventional chemotherapy because it provides antibody-directed targeting, with resultant improvement in therapeutic efficacy and reduced toxicity. Despite extensive research, with notable exceptions, broad clinical application of ADC remains elusive; major hurdles include the instability of antibody–chemotherapy linkers and reduced tumor toxicity of the chemotherapy when bound to the antibody. To address these challenges, we have developed a platform technology that utilizes the nab-paclitaxel formulation of paclitaxel, Abraxane, in which hydrophobic paclitaxel is suspended in 130-nm albumin nanoparticles and thus made water-soluble. We have developed a method to noncovalently coat the Abraxane nanoparticle with recombinant mAbs (anti-VEGF, bevacizumab) and guide Abraxane delivery into tumors in a preclinical model of human A375 melanoma. Here, we define the binding characteristics of bevacizumab and Abraxane, demonstrate that the chemotherapy agent retains its cytotoxic effect, while the antibody maintains the ability to bind its ligand when the two are present in a single nanoparticle (AB160), and show that the nanoparticle yields improved antitumor efficacy in a preclinical human melanoma xenograft model. Further data suggest that numerous therapeutic monoclonal IgG1 antibodies may be utilized in this platform, which has implications for many solid and hematologic malignancies. Cancer Res; 76(13); 3954–64. ©2016 AACR.
AOSSM Early Sport Specialization Consensus Statement
LaPrade, Robert F. , Agel, Julie , Brenner, Joel S. , Cordasco, Frank A. , Feeley, Brian T. , Gould, Daniel , Hainline, Brian , Hewett, Timothy E. , Jayanthi, Neeru , Myer, Gregory D. , Nissen, Carl W. , Provencher, Matthew T. , Hewett, Timothy, Baker, Joseph R. , Cote, Jean Maxime , Engebretsen, Lars , Feeley, Brian T. , Kocher, Mininder Singh , Philippon, Marc J. , Myer, Gregory D , LaPrade, Robert F

Orthopaedic Journal of Sports Medicine | April 29, 2016 | Volume: 4 | Issue: 4 | Pages: No page available

10.1177/2325967116644241 | PMID 27169132 Get It

Background: Early sport specialization is not a requirement for success at the highest levels of competition and is believed to be unhealthy physically and mentally for young athletes. It also discourages unstructured free play, which has many benefits. Purpose: To review the available evidence on early sports specialization and identify areas where scientific data are lacking. Study Design: Think tank, roundtable discussion. Results: The primary outcome of this think tank was that there is no evidence that young children will benefit from early sport specialization in the majority of sports. They are subject to overuse injury and burnout from concentrated activity. Early multisport participation will not deter young athletes from long-term competitive athletic success. Conclusion: Youth advocates, parents, clinicians, and coaches need to work together with the sport governing bodies to ensure healthy environments for play and competition that do not create long-term health issues yet support athletic competition at the highest level desired.
Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Roife, David , Lv, Hailong , Ling, Jianhua , Perez, Mayrim V. Rios , Li, Xinqun, Dai, Bingbing , Pratt, Michael, Truty, Mark J. , Thomas, Ryan M. , Chiao, Paul J. , Katz, Matthew H. G. , Fleming, Jason B. , Kang, Ya’an , Lee, Yeon‐Ju , Suzuki, Rei , Chatterjee, Deyali , Wang, Huamin , Wang, Yu , Koay, Eugene J. , Katz, Matthew H G

Clinical Cancer Research | April 29, 2016 | Volume: 22 | Issue: 19 | Pages: 4934-4946

10.1158/1078-0432.ccr-15-2780 | PMID 27126993 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor is characterized by dense composition of cancer cells, stromal cells, and extracellular matrix (ECM) composed largely of collagen. Within the PDAC tumor microenvironment, activated pancreatic stellate cells (PSC) are the dominant stromal cell type and responsible for collagen deposition. Lumican is a secreted proteoglycan that regulates collagen fibril assembly. We have previously identified that the presence of lumican in the ECM surrounding PDAC cells is associated with improved patient outcome after multimodal therapy and surgical removal of localized PDAC. Experimental Design: Lumican expression in PDAC from 27 patients was determined by IHC and quantitatively analyzed for colocalization with PSCs. In vitro studies examined the molecular mechanisms of lumican transcription and secretion from PSCs (HPSCs and HPaSteC), and cell adhesion and migration assays examined the effect of lumican on PSCs in a collagen-rich environment. Results: Here we identify PSCs as a significant source of extracellular lumican production through quantitative IHC analysis. We demonstrate that the cytokine, TGF-β, negatively regulates lumican gene transcription within HPSCs through its canonical signaling pathway and binding of SMAD4 to novel SBEs identified within the promoter region. In addition, we found that the ability of HPSCs to produce and secrete extracellular lumican significantly enhances HPSCs adhesion and mobility on collagen. Conclusions: Our results demonstrate that activated pancreatic stellate cells within PDAC secrete lumican under the negative control of TGF-β; once secreted, the extracellular lumican enhances stellate cell adhesion and mobility in a collagen-rich environment. Clin Cancer Res; 22(19); 4934–46. ©2016 AACR.
Commentary
Drake, Matthew T.

Clinical Chemistry | April 28, 2016 | Volume: 62 | Issue: 5 | Pages: 687-688

10.1373/clinchem.2015.248757 | PMID 27127242 Get It

Sulfate transporters involved in sulfate secretion in the kidney are localized in the renal proximal tubule II of the elephant fish (Callorhinchus milii)
Hasegawa, Kumi , Kato, Akira , Watanabe, Taro , Takagi, Wataru , Romero, Michael F. , Toop, Tes, Hyodo, Susumu , Bell, Justin D. , Donald, John Alexander , Romero, Michael F , Kato, Akira

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | April 28, 2016 | Volume: 311 | Issue: 1 | Pages: R66-R78

10.1152/ajpregu.00477.2015 | PMID 27122370 Get It

Most vertebrates, including cartilaginous fishes, maintain their plasma SO42−concentration ([SO42−]) within a narrow range of 0.2–1 mM. As seawater has a [SO42−] about 40 times higher than that of the plasma, SO42−excretion is the major role of kidneys in marine teleost fishes. It has been suggested that cartilaginous fishes also excrete excess SO42−via the kidney. However, little is known about the underlying mechanisms for SO42−transport in cartilaginous fish, largely due to the extraordinarily elaborate four-loop configuration of the nephron, which consists of at least 10 morphologically distinguishable segments. In the present study, we determined cDNA sequences from the kidney of holocephalan elephant fish ( Callorhinchus milii) that encoded solute carrier family 26 member 1 (Slc26a1) and member 6 (Slc26a6), which are SO42−transporters that are expressed in mammalian and teleost kidneys. Elephant fish Slc26a1 (cmSlc26a1) and cmSlc26a6 mRNAs were coexpressed in the proximal II (PII) segment of the nephron, which comprises the second loop in the sinus zone. Functional analyses using Xenopus oocytes and the results of immunohistochemistry revealed that cmSlc26a1 is a basolaterally located electroneutral SO42−transporter, while cmSlc26a6 is an apically located, electrogenic Cl−/SO42−exchanger. In addition, we found that both cmSlc26a1 and cmSlc26a6 were abundantly expressed in the kidney of embryos; SO42−was concentrated in a bladder-like structure of elephant fish embryos. Our results demonstrated that the PII segment of the nephron contributes to the secretion of excess SO42−by the kidney of elephant fish. Possible mechanisms for SO42−secretion in the PII segment are discussed.
Hypertrophic Cardiomyopathy—One Case per Year?
Ommen, Steve R. , Nishimura, Rick A.

JAMA Cardiology | April 28, 2016 | Volume: 1 | Issue: 3 | Pages: 333

10.1001/jamacardio.2016.0277 | PMID 27438115 Get It

Education on, Exposure to, and Management of Vascular Anomalies During Otolaryngology Residency and Pediatric Otolaryngology Fellowship
Jabbour, Noel , Balakrishnan, Karthik , Darrow, David H., Elluru, Ravindhra G., Grimmer, J. Fredrik , Richter, Gresham T. , Shin, Jennifer J. , Chun, Robert H. , Bauman, Nancy M. , Perkins, Jonathan A. , Balakrishnan, Karthik

JAMA Otolaryngology–Head & Neck Surgery | April 28, 2016 | Volume: 142 | Issue: 7 | Pages: 648

10.1001/jamaoto.2016.0605 | PMID 27124736 Get It

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
McCall, Andrew N., Ingimarsson, Johann P. , Morrisson, Griffin T., Hook, C. Christopher , Krambeck, Amy E. , Hook, Christopher C.

Journal of Endourology Case Reports | April 28, 2016 | Volume: 2 | Issue: 1 | Pages: 81-83

10.1089/cren.2016.0048 | PMID 27579425 Get It

Abstract Background: Percutaneous nephrolithotomy (PCNL) for large stone burden can be problematic in patients with significant risk of bleeding complications, specifically thrombocytopenia. This report demonstrates effective correction of two patients' thrombocytopenia, subsequently leading to removal of large stone burden through PCNL. Case Presentation: We present two Middle Eastern patients who presented with medical histories significant for thrombocytopenia, secondary to splenomegaly and hepatic vein thrombosis, and large volume nephrolithiasis. Patient 1 is a 65-year-old female with a right 5 cm stone and a platelet count of 34,000. Patient 2 is a 45-year-old female with a 3 cm left staghorn stone and a platelet count of 44,000. After consultation with hematology, both underwent therapy with prednisone and intravenous immunoglobulin without improvement in their platelet count. They then received 3 μg/kg/dose of romiplostim weekly that improved their platelet counts to 133,000 and 195,000 in 2 weeks, respectively. Patient 1's PCNL was completed in a single-stage procedure with stone-free status shown on CT postoperative day 1. Patient 2 underwent PCNL and a secondary ureteroscopy for residual stone fragments on postoperative day 2. Both patients experienced no complication during the procedure, hospital stay, or postoperative course. Both continued romiplostim for 20 days postoperatively with platelet levels returning to their baseline range after 1 month. Conclusion: In the appropriately selected patient, romiplostim can correct thrombocytopenia enough to safely and effectively perform PCNL in patients with underlying hematologic disorders. Close coordination between urology and hematology is imperative to ensure an effective outcome in this challenging patient population.